These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18027986)

  • 1. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
    Klotz U
    Clin Pharmacokinet; 2007; 46(12):985-96. PubMed ID: 18027986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic agents: drug interactions of clinical significance.
    Trujillo TC; Nolan PE
    Drug Saf; 2000 Dec; 23(6):509-32. PubMed ID: 11144659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
    Mehvar R; Brocks DR; Vakily M
    Clin Pharmacokinet; 2002; 41(8):533-58. PubMed ID: 12102640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is antiarrhythmic treatment in the elderly different? a review of the specific changes.
    Deneer VH; van Hemel NM
    Drugs Aging; 2011 Aug; 28(8):617-33. PubMed ID: 21812498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.
    Kim SY; Benowitz NL
    Drug Saf; 1990; 5(6):393-420. PubMed ID: 2285495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of antiarrhythmic drug plasma concentration monitoring.
    Follath F; Ganzinger U; Schuetz E
    Clin Pharmacokinet; 1983; 8(1):63-82. PubMed ID: 6404580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics in heart failure. An updated review.
    Shammas FV; Dickstein K
    Clin Pharmacokinet; 1988 Aug; 15(2):94-113. PubMed ID: 3064953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
    Lévy RH; Lévy S; Bricaud H
    Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1229-35. PubMed ID: 6778416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect.
    Drvota V; Carlsson B; Häggblad J; Sylvén C
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):222-6. PubMed ID: 7475046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
    Bosilkovska M; Walder B; Besson M; Daali Y; Desmeules J
    Drugs; 2012 Aug; 72(12):1645-69. PubMed ID: 22867045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.
    Anderson GD
    Clin Pharmacokinet; 2005; 44(10):989-1008. PubMed ID: 16176115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
    Fleishaker JC
    Clin Pharmacokinet; 2000 Dec; 39(6):413-27. PubMed ID: 11192474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment.
    El-Khateeb E; Darwich AS; Achour B; Athwal V; Rostami-Hodjegan A
    Aliment Pharmacol Ther; 2021 Aug; 54(4):388-401. PubMed ID: 34218453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
    Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.